Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
3
pubmed:dateCreated
1985-3-27
pubmed:abstractText
The cell surface density of high-affinity membrane receptors for the T-lymphocytotrophic hormone interleukin 2 (IL-2) determines the rate of T-cell-cycle progression. Since 10-fold greater numbers of IL-2 receptor molecules were found by using a radiolabeled monoclonal antibody reactive with IL-2 receptors (anti-Tac) compared with binding of IL-2, the functional relationship of the binding sites recognized by both of these ligands was assessed. In the presence of cycloheximide, IL-2 binding sites declined with a half-time (t1/2) of 2.6 hr, whereas the decay of anti-Tac binding sites was much slower (t 1/2 = 6.4 hr). Moreover, after limited membrane proteolysis, the half-time for the reappearance of IL-2 binding sites was remarkably similar to its decay (t 1/2 = 2.2 hr), while Tac antigen reappearance was markedly retarded, returning to only 20% of original levels within 5 hr after proteolysis. Addition of homogeneous immunoaffinity-purified IL-2 to cell populations that expressed equivalent IL-2 and anti-Tac binding sites resulted in a time- and temperature-dependent 8- to 10-fold enhancement of Tac epitope expression and, simultaneously, a 20-30% diminishment of detectable high-affinity IL-2 binding sites. As the magnitude of the IL-2-dependent proliferative response correlated with the density of high-affinity IL-2 binding sites, rather than Tac antigen levels, quantitation of Tac epitope density does not provide a reliable indication of IL-2-responsiveness among activated T-cell populations. Instead, IL-2-receptor interactions actually promote the loss of IL-2 responsiveness by diminishing the density of high-affinity binding sites at the time that Tac antigen levels are increased.
pubmed:grant
pubmed:commentsCorrections
http://linkedlifedata.com/resource/pubmed/commentcorrection/2983318-141483, http://linkedlifedata.com/resource/pubmed/commentcorrection/2983318-145543, http://linkedlifedata.com/resource/pubmed/commentcorrection/2983318-181845, http://linkedlifedata.com/resource/pubmed/commentcorrection/2983318-455445, http://linkedlifedata.com/resource/pubmed/commentcorrection/2983318-571871, http://linkedlifedata.com/resource/pubmed/commentcorrection/2983318-6090948, http://linkedlifedata.com/resource/pubmed/commentcorrection/2983318-6090949, http://linkedlifedata.com/resource/pubmed/commentcorrection/2983318-6231642, http://linkedlifedata.com/resource/pubmed/commentcorrection/2983318-6288686, http://linkedlifedata.com/resource/pubmed/commentcorrection/2983318-6327813, http://linkedlifedata.com/resource/pubmed/commentcorrection/2983318-6328312, http://linkedlifedata.com/resource/pubmed/commentcorrection/2983318-6352804, http://linkedlifedata.com/resource/pubmed/commentcorrection/2983318-6413637, http://linkedlifedata.com/resource/pubmed/commentcorrection/2983318-6427923, http://linkedlifedata.com/resource/pubmed/commentcorrection/2983318-6443342, http://linkedlifedata.com/resource/pubmed/commentcorrection/2983318-6606011, http://linkedlifedata.com/resource/pubmed/commentcorrection/2983318-6815536, http://linkedlifedata.com/resource/pubmed/commentcorrection/2983318-6975347, http://linkedlifedata.com/resource/pubmed/commentcorrection/2983318-7195778
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Feb
pubmed:issn
0027-8424
pubmed:author
pubmed:issnType
Print
pubmed:volume
82
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
864-8
pubmed:dateRevised
2009-11-18
pubmed:meshHeading
pubmed:year
1985
pubmed:articleTitle
Interleukin 2 regulates its own receptors.
pubmed:publicationType
Journal Article, Research Support, U.S. Gov't, P.H.S.